The identification of somatic alterations with a cancer promoting role is challenging in highly unstable and heterogeneous cancers, such as esophageal adenocarcinoma (EAC). Here we used a machine learning approach to identify cancer genes in individual patients considering all types of damaging alterations simultaneously (mutations, copy number alterations and structural rearrangements).
INTRODUCTION
Genome instability enables the onset of several hallmarks of cancer because acquired alterations can confer selective advantages to the mutated cells, thus driving their outgrowth and eventual dominance 1 . The identification of driver genes (the genes acquiring the driver alterations) is critical to fully understand the molecular determinants of cancer and to inform the development of precision oncology. Since driver genes are under positive selection during cancer progression, a reasonable assumption is that they mutate more frequently than expected. Over the past years, large-scale cancer genomic studies have provided the required power to detect driver events recurring across samples with good statistical confidence 2, 3 . However, the full characterisation of driver events is particularly challenging when the genomic landscape of the cancer is highly variable and recurrent events are relatively few.
One such cancer is esophageal adenocarcinoma (EAC), which shows high mutational and chromosomal instability leading to widespread genetic heterogeneity.
In recent years, EAC incidence has risen substantially in the western world 4, 5 , causing more than 400,000 deaths each year 6 . In over 400 EACs sequenced so far, mutations in TP53, CDKN2A, SMARCA4, ARID1A, SMAD4, ERBB2 as well as amplifications of VEGFA, ERBB2, EGFR, GATA4/6, CCNE1 are the only recurrent driver events [7] [8] [9] [10] [11] [12] . This leaves up to 10-20% of patients without known genetic determinants and often the number of identified drivers per sample is too low to fully explain the disease. As a consequence of this heterogeneity, the molecular mechanisms that drive EAC have been difficult to characterise in full. This has a profound impact on the way in which EAC is currently diagnosed and treated. For example, EAC treatment is still largely based on conventional chemotherapy and phase III clinical trials with various targeted agents have failed to show benefits or reached inconclusive results [13] [14] [15] .
Here we hypothesise that, alongside the critical role of recurrent and wellknown drivers, complementary somatic alterations of several other genes help cancer progression in individual patients. Therefore, for a comprehensive characterisation of the molecular determinants relevant to cancer, both recurrent and patient-specific cancer genes should be considered. However, while recurrent drivers can be identified based on the frequency of alterations, genes that act to promote cancer in individual patients are difficult to recognise. To this aim, we developed a machine-learning method, sysSVM, based on the rationale that somatic alterations sustaining cancer affect genes with specific properties 16 . Using these properties, rather than recurrence, allows patient-specific predictions.
We applied sysSVM to 261 EACs from the UK OCCAMS Consortium. We first trained the classifier using 34 properties specific to known cancer genes and then prioritised 908 genes that, together with the known drivers, help or promote cancer development in the whole EAC cohort. The large majority of these newly predicted 'helper' genes are rare or patient-specific, however they converge towards the perturbation of related biological processes. Several of these processes are wellknown players in cancer development including cell cycle control, DNA replication, proteasome activity, Toll-like receptor signalling, and downstream effectors of intracellular signalling. We used the recurrence of process perturbation, rather than genes, to stratify the 261 EACs into six clusters that show distinct molecular features and suggest differential response to targeted treatment.
RESULTS
The landscape of patient-specific cancer genes in EAC sysSVM applies machine learning to predict altered genes contributing to cancer based on the similarity of their molecular and systems-level properties to those of known cancer genes (Supplementary text). Molecular properties derive from cancer sequencing data and include somatic alterations with a predicted damaging effect on the protein function (gene gains and losses, translocations, inversions, insertions, truncating and non-truncating damaging alterations and gain of function mutations) as well as the overall mutation burden and the gene copy number (Supplementary Table 1 ). Systems-level properties are genomic, epigenomic, evolutionary and gene expression features that distinguish cancer genes from other genes. They include gene length and protein domain organisation 16, 17 , gene duplicability 18, 19 , chromatin state 20 , connections and position of the encoded proteins in the protein-protein interaction network 18 , number of associated regulatory miRNAs 19 , gene evolutionary origin 19 and breadth of gene expression in human tissues 16, 17 ( Supplementary Table 1 ). sysSVM is composed of three steps (Supplementary text, Figure 1A ). In the first step, all altered genes in each cancer sample are annotated in terms of 10 molecular and 24 systems-level properties. In the second step, molecular and systems-level properties of the known cancer genes altered within the cancer sample cohort are used to train a one-class support vector machine using four kernels (linear, sigmoid, radial, polynomial). In the third step, the four best classifiers from the training (one per kernel) are used for prediction. All remaining altered genes are first scored in each patient individually by combining the corresponding decision values in the four kernels. Genes are then ranked in each patient according to the resulting combined score. Methods for the identification of cancer drivers usually apply statistical models and a well-defined cut-off (usually a p-value) to distinguish drivers from passenger events. Since our hypothesis is that the strength of the contribution of a gene to cancer depends on how similar its properties are to those of known cancer genes, our score reflects a gradient between driver and passenger activity. The contribution of a gene to cancer decreases with its decreasing similarity to known cancer genes and with its score. Therefore, we do not define a hard cut-off. Rather, the top scoring genes are the most similar to known cancer genes and are the most likely contributors to cancer progression in that patient.
We applied sysSVM to 261 EACs from OCCAMS which are part of the International Cancer Genome Consortium (ICGC) dataset ( Figure 1B , Supplementary Table 2 ). In the first step, we extracted 17,078 genes with predicted damaging alterations in the whole cohort (median of 382 damaged genes per patient, Supplementary Table 2 ). In the second step, we optimised the parameters and trained the four classifiers using 476 known cancer genes 21 altered in the cohort (Supplementary Table 3 , Supplementary Table 4 ). As expected, known cancer genes tend to occupy specific regions of the feature space according to their molecular and systems-level properties ( Supplementary Figure 1 ). In the third step, we scored and ranked the remaining 16,602 genes ( Figure 1B ). Overall, top scoring genes localise to the same high-density regions of known cancer genes ( Figure 1C) , with lower scoring genes being further away from them (Supplementary Figure 2 ). This indicates that the properties of top scoring genes indeed resemble those of known cancer genes. To evaluate how sysSVM classifier trained on the ICGC cohort performs on independent cohorts, we used 86 EACs from The Cancer Genome Atlas (TCGA) and 21 EACs from a previous study 22 (Supplementary Table 2 ). We scored all altered genes, including known cancer genes, in each of the 107 EACs independently, using the four classifiers trained on the ICGC cohort. In both datasets, known cancer genes (e.g. TP53, ERBB2, EGFR, SMAD4) have significantly higher scores than the rest of the altered genes (Supplementary Figure   2 ), indicating that sysSVM is able to recognise them as major cancer contributors.
Since we do not use a statistical cut-off to distinguish driver from passenger genes, we arbitrarily considered the top 10 scoring genes in each patient as the main cancer contributors for that patient. We verified that -as expected -the main findings of our study hold true if we apply higher or lower cut offs (see below). This led to a total of 908 genes (Supplementary Table 5 ). Since our hypothesis is that these genes help the known drivers altered in the same sample to promote cancer, we define them as 'helper genes'. Consistent with the prevalence of gene amplification in EAC ( Supplementary Table 1 ), the vast majority of newly predicted helpers undergo copy number gain ( Figure 1D ) and are rare or patient-specific ( Figure 1E) . A few helper genes, however, are altered in more than 10% of EACs (Supplementary Table 5 ) and are usually associated with frequently occurring amplification events 11 (Supplementary Figure 3) . Interestingly, around 10% of helpers (86 genes) have been predicted as candidate cancer genes in previous studies 17 , and 39 have recently been added to Tiers 1 and 2 of the Cancer Gene Census 23 (Supplementary Table 5 ). As a further assessment of sysSVM predictions, we searched for possible false positives among the helpers using two lists. The first is composed of 14 genes that have previously been considered as recurrent false positives of driver prediction 2 and only one is a predicted cancer helper (PCLO).
PCLO is considered as a false positive because of its long coding sequence and biased base composition 2 . However, PCLO is amplified and not mutated in EAC (Supplementary Table 5 ) and recently it has been shown to exert an oncogenic role in esophageal cancer by interfering with the EGFR signalling pathway 24 . The second list is a manually curated set of 488 genes 3 . We found 37 helpers in this list (4% of the total), which is less than the known cancer genes from the Cancer Gene Census (46/719, 6.4%). Therefore, sysSVM robustly predicts cancer genes in multiple patient cohorts, with a minimal false positive rate.
Patient-specific helpers converge to perturb related biological processes
Alterations in the newly predicted helper genes in the OCCAMS cohort are mostly rare or patient-specific ( Figure 1D ). In order to gain insight into their cancer promoting functions and gather a comprehensive characterisation of the molecular determinants of EAC, we analysed the biological processes perturbed by helpers compared to drivers. To this aim, we manually reviewed all 476 known cancer genes 21 with damaging alterations in the OCCAMS cohort and retained 202 of them based on the concordance between the type of acquired modification and the literature evidence of their cancer role (Methods, Supplementary Table 3 ). The median number of drivers per EAC is in accordance with recent estimates 25, 26 and the majority of them undergo gene amplification (Supplementary Figure 3 ). We performed two independent gene set enrichment analyses, one with the 202 known drivers and one with 908 helpers, to dissect their relative functional contribution to EAC. This led to 297 and 365 enriched pathways out of the 1,877 tested, respectively (FDR <0.01, Supplementary Table 6 , Supplementary Figure 3 ).
Approximately 30% of pathways (84) enriched in known drivers are perturbed in more than 50% of EACs (Supplementary Table 6 ). These 'universal' pathways are involved in well-known cancer-related processes, such as intracellular signalling, cell cycle control, apoptosis, and DNA repair (Supplementary Figure 4 ) and are associated with the most recurrently altered known drivers (TP53, CDKN2A, MYC, ERBB2, SMAD4, CDK6, KRAS, Supplementary Table 3 ). Interestingly, 59 universal pathways (70% of the total) are also enriched in helpers, often in patients with no known drivers in that pathway (Figure 2A , Supplementary Table 6 ). This indicates that helpers also contribute to the perturbation of key cancer pathways and that their alteration may be sufficient for cancer development in some EACs.
Next, we clustered EACs according to the proportion of perturbed pathways that they have in common (Methods, Figure 2B ). When using pathways enriched in known drivers, the clustering is dominated by the most recurrently altered genes and EACs are broadly divided in two groups depending on TP53 mutated (75,5% of the total) or wild-type status ( Figure 2C , D, Supplementary Table 2 ). Similarly, smaller clusters are driven by the mutational status of other recurrent drivers (for example EGFR and ERBB2 in cluster 1D, MYC, EGFR and ERBB2 in cluster 2D, MYC and KRAS in cluster 3D, Figure 2C , D). Samples with no alterations in TP53 (clusters 5D and 6D) show an overall lower mutational burden (p = 0.001, Wilcoxon rank sum test), fewer known drivers and consequently a lower number of enriched pathways (p = 2x10 -6 , Wilcoxon rank sum test, Supplementary Figure S3 ).
When grouping EACs according to the pathways enriched in helpers, six clusters can be identified (clusters 1H-6H, Figure 2C ) where samples are brought together not by the recurrent alterations of specific genes, but by several altered helpers mapping to the same or related pathways (Supplementary Table 2 ). We refer to these related pathways that define the clusters as 'biological processes'. For Table 2 ). EACs in this cluster show significant alterations of known drivers such as GNAS, SS18L1, and TRRAP (FDR <0.03, Fisher's exact test). Interestingly, TRRAP is a E2F cofactor and stimulates E2Fmediated transcription when overexpressed 27 . Alterations in the E2F family and associated co-factors may help cancer progression by contributing to increased genomic instability through aberrant cell-cycle control 28, 29 . Consistently with this, EACs in cluster 1H accumulate significantly more gene amplifications and damaging alterations as compared to other clusters (FDR <2.2 -16 and FDR <0.05, Wilcoxon rank-sum test, Figure 3A , B). They are also enriched in the mutational signature S17A (FDR <0.18, Wilcoxon rank-sum test, Figure 3C ), typical of highly mutagenic Figure 3C ), which in EAC has been associated with defects in homologous recombination 11 . Cluster 4H shows perturbations in the Toll-like receptor signalling cascade (Supplementary Figure 5 ) that has recently been reported to be dysregulated in EAC 30 . Cluster 5H harbours perturbations in DNA replication, with recurrent alterations in members of the MCM complex (Supplementary Table 2 ). Interestingly, MCMs are targets of E2F1 31, 32 , and their dysregulation induces replicative stress and increases genomic instability 28 . This is consistent with the observation that EACs in cluster 5H also have significantly higher exposure to mutational signatures S3 and S2 (FDR <0.06 and 0.9, respectively, Figure 3C ). Therefore, clusters 1H and 5H converge towards the disruption of related processes through several distinct genes. Overall, clusters 1H to 5H account for 151 EACs (58% of the total cohort). The remaining 110 EACs in cluster 6H share fewer perturbed pathways, although the majority of them have alterations in Rho GTPase activity (Supplementary Figure 5 ) with frequent modifications of Rho GTPases and their effectors such as and CDC42, ROCK1, PAK1, NDE1 and ABI2 (Supplementary Table 2 ). EACs in the six clusters obtained using helpers are broadly dispersed in the clustering of known drivers ( Figure 2C ) indicating that helpers bring together patients with similar perturbed processes that cannot be appreciated when focussing only on recurrent drivers.
To test whether the clustering is affected by considering only the top 10 helper genes in each patient, we performed the same analysis considering as helpers the top five or top 15 scoring helper genes (487 and 1,282 unique genes, respectively).
We found that the vast majority (92% and 78%) of the pathways enriched in these two datasets are also enriched when considering the top 10 helpers (Supplementary Figure 6 ). This indicates that the recurrently perturbed processes are highly overlapping. We then clustered EACs according to the proportion of common perturbed pathways and verified that the six clusters obtained using pathways enriched in top 10 genes recapitulated well the clusters obtained using pathways enriched in top five or 15 genes (Supplementary Figure 6 ). Therefore, the clustering is robust regardless of the applied score cut off.
Helper alteration contributes to cancer-related phenotypes
To test the contribution of EAC helper genes towards the perturbation of cellular processes, we experimentally assessed the consequences of altering representative helpers. We used EAC FLO-1 cells because all helper genes selected for validation are expressed in these cells and have no mutations or copy number alterations 33 , allowing a clear evaluation of the effect of their alteration. As a main hallmark of cancer 3, 34 , we assessed the effect of helper alterations on cell proliferation but also performed gene-specific assays to further investigate the effect of specific helper perturbations.
First, we started from representatives of clusters 1H and 5H that are functionally related and selected the most commonly altered helpers, E2F1 (25 out of 35 samples in cluster 1H) and MCM7 (22 out of 26 samples in cluster 5H, Supplementary Table 2 ). The transcription factor E2F1 promotes G1-S transition and regulates DNA replication, while MCM7 is part of the MCM complex, which is loaded onto chromatin throughout G1 and is activated at the start of S phase ( Figure 4A ).
Both E2F1 and MCM7 are amplified in EACs (Supplementary Table 5 ) leading to significant gene overexpression (median two-fold increase, p=0.005 and p=0.001, respectively Wilcoxon rank-sum test; Figure 4B ). To mimic their amplification in EAC, we stably overexpressed E2F1 and MCM7 in FLO-1 cells to levels comparable to those observed in EAC patients ( Figure 4C ). In both cases we observed significantly higher proliferation of overexpressing cells as compared to control cells (p<10 -4 and p=0.0006, respectively, one-tailed T-test; Figure 4D ). Since E2F1 promotes cell cycle progression, we assessed the replication rate by measuring EdU incorporation during the cell cycle. We observed increased EdU intensity throughout S phase in E2F1 overexpressing cells as compared to control cells (p<10 -4 , Mann Whiney U test; Figure 4E ). This suggests that E2F1 may help cancer growth by promoting S phase entry. To assess the functional consequence of MCM7 overexpression on the MCM complex, we measured its loading onto chromatin. We observed that MCM7 overexpressing cells display a lower MCM fluorescence intensity overall as compared to control cells when staining the chromatin-bound fraction for either MCM7 or MCM3 (p<10 -4 , Mann-Whitney U test; Figure 4F , 4G). This suggests that less MCM complex is loaded onto chromatin by the start of S phase. Therefore, MCM7 overexpression leads to both increased proliferation and perturbation of MCM complex activity, possibly through independent mechanisms 35 .
E2F1 and MCM7 are among the most frequently altered helpers in our cohort (~10% of EACs). To evaluate the role of rare helpers, we tested NCOR2 that is altered in four EACs (1,5% of the total, Supplementary Table 5 ). NCOR2 is part of the nuclear receptor corepressor complex that favours global chromatin deacetylation and transcriptional repression 36, 37 (Figure 5A ). Consistently with the tumour suppressor role that has been suggested for NCOR2 in lymphoma and prostate cancer 38, 39 , the most frequent NCOR2 alterations in EAC lead to loss of function. Therefore, we edited the gene in FLO-1 cells using a vector-free CRISPR system 40 . Three pooled crRNAs were co-transfected with Cas9 and the tracrRNA (Methods, Supplementary Table 7 ) and the editing was confirmed and quantified using Miseq ( Figure 5B ). Supporting a tumour suppressor role for NCOR2, we observed that the edited cells proliferate more than control cells (p<10 -4 , one-tailed T-test test; Figure 5C ).
Finally, we tested the effect of altering members of the Rho GTPase effector pathway, which is pervasively perturbed in all six clusters, including 6H (Supplementary Table 2 ). This pathway contains several, often patient-specific helpers that modulate actin cytoskeletal dynamics, cell proliferation and migration ( Figure 5D , Supplementary Table S5 ). Two such effectors, ABI2 and PAK1, undergo damaging alterations and amplification in seven and nine EACs, respectively (Supplementary Table 5 ). We therefore edited ABI2 and overexpressed PAK1 as described above (Supplementary Table 7 , Figure 5E ) and in both cases observed significantly increased proliferation as compared to control cells (ABI2: p<10 -4 , PAK1: p=10 -3 one-tailed T-test; Figure 5F ).
Taken together these data indicate that, independent of the frequency of the alteration, the modification of predicted helpers has an effect on promoting cell growth. Moreover, it is the perturbation of a biological process, rather than a specific gene, that acts to promote cancer.
DISCUSSION
Most state-of-the-art approaches to discovering cancer driver events rely on the detection of positively selected alterations of genes that are functionally beneficial for cancer development 3, 25 . Even ratiometric methods based on gene properties 41 ultimately assess the effect of positive selection and distinguish the few selected drivers from the many passenger events. As a result, the discovery of cancer drivers is biased towards genes that are frequently altered across patients. This poses significant limitations for cancers such as EAC that have a highly variable but mostly flat (i.e. with few recurrent events) mutational landscape. In support of this, the overall selection acting on esophageal cancer genomes is among the lowest across cancer types 25 , despite a median of 382 damaged genes per EAC (Supplementary Table 2 ). This indicates that the exclusive focus on genes under strong selection is likely to return only a partial representation of the genes important for EAC.
To overcome these limitations, our machine learning approach ranks somatically altered genes that are relevant for cancer based on their properties rather than mutation recurrence. Another advantage of not measuring selection is that sysSVM considers all types of gene alterations (SNVs, indels, CNVs, and structural variations) simultaneously. Therefore, sysSVM provides a comprehensive overview of the genetic modifications that play a cancer promoting role in each patient. When applied to 261 EACs from ICGC, sysSVM prioritises 908 altered genes that, together with known drivers, help cancer progression. This large number of helper genes is in agreement with the recent observation of a positive correlation between mutational burden and number of driver genes, which is only partially explained by a sample size effect 3 . We speculate that this positive correlation may indicate that the number of functionally relevant genes increases with the number of altered genes.
The heterogeneous landscape of EAC cancer genes is substantially reduced by considering the perturbed biological processes rather than individual genes ( Figure 2C ). Several of these processes are well-known contributors to cancer development, including intracellular signalling, cell cycle control, and DNA repair ( Supplementary Table 6 ). Interestingly, while the known drivers tend to encode upstream players in these pathways, helpers are often downstream effectors. For example, we found several Rho GTPase effectors ( Figure 5D , Supplementary Table  5 ) or genes downstream of previously reported EAC drivers in the Toll-like receptor cascade ( Supplementary Table 5 ). This supports a more local role of helpers in contributing to cancer at the single patient level, possibly by sustaining or complementing the function of drivers. In this respect, helpers are conceptually similar to mini-drivers 42 .
Analysing the pathways disrupted by helpers allows the division of the 261 EACs into six functional clusters that often have similar molecular features, such as the prevalence of the same mutational signatures or the association with known drivers ( Figure 2D and Figure 3C ). For example, two of these clusters (1H and 5H) are closely related in function, showing perturbations of processes involved in the control of S-phase entry and DNA replication. Consistent with this, they bring together the most genomically unstable samples. By experimentally mimicking the amplification of E2F1 (representative of cluster 1H) and MCM7 (representative of cluster 5H), we induced increased proliferation in EAC cells ( Figure 4D ). We also provide evidence that E2F1 increases proliferation by promoting S phase entry ( Figure 4E ). Interestingly, MCM7 overexpression resulted in a reduction of MCM complex loading onto chromatin ( Figure 4F and 4G) , maybe due to a stoichiometric imbalance of complex subunits. This may indicate that MCM7 promotes cell growth through a separate mechanism besides its function in the MCM complex. For example, MCM7 interacts with the tumour suppressor protein Rb, a wellcharacterised inhibitor of E2F1 43 . It is possible that MCM7 overexpression may sequester Rb away from E2F1, thereby promoting E2F1-mediated cell cycle progression. While the majority of patients with MCM7 amplification are grouped in cluster 5H, several patients in cluster 1H also have amplification of MCM7 (Supplementary table 2) , supporting an overlapping role for MCM7 and E2F1 towards the perturbation of similar pathways involved in cell cycle control.
We also confirmed the cancer promoting role of very rare helpers, such as ABI2, NCOR2 and PAK1 that are altered in 1.5% to 3.4% of EACs ( Figure 5C Table 2 ). The proteasome can be targeted by small molecules such as bortezomib, which is currently used in myeloma and lymphoma and is in clinical trials for the treatment of solid tumours 44 . Approximately 7% of EACs in our cohort harbour alterations in proteasome-related helpers and it is tempting to speculate that these alterations could be used to stratify patients who may benefit from proteasome inhibition. Interestingly, proteasome inhibition has been shown to have a synergic effect in combination with ERBB2 inhibitors 45 . Since ERBB2 is also significantly altered in cluster 2H ( Figure 2D ), a combined therapy may be beneficial to patients in this cluster.
In summary, we provide one of the first attempts to extend the discovery of acquired perturbations contributing to cancer beyond those of recurrent drivers.
Additional efforts are required to fully exploit the potential of these approaches to offer a more comprehensive view of the molecular mechanisms behind cancer and to guide novel clinical interventions.
METHODS

Annotation of molecular properties
Data on somatic single nucleotide variations (SNVs), small insertions and deletions (indels), copy number variations (CNVs), structural variations (SVs), and mutational signatures for 261 EACs were obtained from ICGC and analysed as previously described 11 (Supplementary Table 2 ). Briefly, SNVs and indels were called using Strelka v.1.0.13 46 and subsequently filtered as previously described 11 . For CNVs, the absolute copy number for each genomic region was obtained from ASCAT-NGS v.2.1 47 after correction for tumour content, using read counts at germline heterozygous positions as derived from GATK v.3.2-2 48 . To account for the high number of amplifications occurring in EAC, copy number gains were corrected by the ploidy of each sample as estimated by ASCAT-NGS. A gene was assigned with the copy number of a CNV region if at least 25% of its length was contained in that region. SVs (gene translocations, inversions, insertions) were identified from discordant read pairs using Manta 49 after excluding SVs that were also present in more than two normal samples of a panel of 15 esophagus and 50 blood samples 11 .
In the case of TCGA validation cohort, SNVs, indels, and CNVs were derived from level 3 TCGA annotation data of 86 EACs (https://portal.gdc.cancer.gov/projects/TCGA-ESCA, Supplementary Table 2 ). In the case of 21 EACs from a previous study 22 , SNVs, indels, and CNVs were called as described for the ICGC samples (Supplementary Table 2 ). The distribution of variant allele frequency of SNVs and indels across all samples was used to remove outliers likely indicating sequencing or calling artefacts. Variants with <10% frequency and indels longer than five base pairs were also removed. For CNVs, genomic regions were considered as amplified or deleted if their segment mean was higher than 0.3 or lower than -0.3, respectively, capping the segment mean to 1.5 to avoid hypersegmentation 50 . A gene was considered as amplified or deleted if at least 25% of its length was contained in a CNV region and the resulting copy number (CN) was estimated as:
No SV data were available for the validation cohorts.
Since only genes with predicted damaging alterations were used as input for sysSVM, further annotation for the variant damaging effect was performed. Stopgain, stoploss, frameshift, nonframeshit, nonsynonymous, and splicing SNVs and indels were annotated using ANNOVAR (December 2015) 51 . All truncating alterations (stopgain, stoploss, and frameshift mutations) were considered as damaging. Table 1 ). Of these, 476 were known cancer genes 21 , corresponding to 4,091 redundant genes (Supplementary Table 2 ). For all 17,078 genes, the total number of exonic alterations (silent and nonsilent) and the somatic copy number were used as additional molecular features in sysSVM.
Annotation of systems-level properties
Protein sequences from RefSeq v.63 63 were aligned to the human reference genome assembly GRCh37 to define unique gene loci as previously described 17 . The length of the longest coding sequence was taken as the gene length. Genes aligning to more than one gene locus for at least 60% of the protein length were considered as duplicated genes 18 MIntAct v.190 67 ; DIP (April 2015) 68 ; HPRD v.9 69 ; the miRNA-gene interactions were derived from miRTarBase v.4.5 70 and miRecords (April 2013) 60 ; gene evolutionary origin was assessed as described in D'Antonio et al., 2011 19 using gene orthology from EggNOG v.4 71 ; and gene expression in 30 normal tissues was retrieved from
GTEx v.1.1.8 72 . Except gene length, duplication and ohnologs, all other systemslevel properties had missing information for some of the 17,078 altered genes (Supplementary Table 1 ). To account for this, median imputation for continuous properties and mode imputation for categorical properties were implemented.
Specifically, for each property median or mode values were calculated for known cancer genes and the rest of mutated genes. All missing values were replaced with their corresponding median or mode values.
Application of sysSVM to EACs
To train SysSVM, 476 known cancer genes with damaging alterations in 261 EACs Table 5 ).
(Supplementary
Identification of perturbed processes and patient clustering
To identify the perturbed biological processes in the EAC cohort, both predicted cancer helper genes and known cancer driver genes were used. A manual revision of 476 known cancer genes altered in the ICGC cohort was performed and genes were considered as known drivers if (1) their somatic alteration had been previously associated with EAC, (2) they had a loss-of-function alteration and their tumour suppressor role had been reported in other cancer types 73 , (3) they had a gain-offunction alteration and their oncogenic role had been reported in other cancer types 73 . The resulting 202 known cancer drivers (Supplementary Table 3 ) and 908 cancer helpers were used for the gene set enrichment analysis against Reactome v.58 74 , composed of 1,877 pathways and 10,131 genes. After excluding pathways in levels 1 and 2 of Reactome hierarchy and those with less than 10 or more than 500 genes, 1,155 pathways were retained. These contained 9,061 genes, including 155 known drivers and 619 helpers. Gene set enrichment was assessed using one-tailed hypergeometric test and the resulting P values were corrected for multiple testing using the Benjamini & Hochberg method (Supplementary Table 6 ). Enriched pathways within the sets of known drivers or helpers were subsequently used to cluster samples taking into account the proportion of perturbed processes shared between samples. The Jaccard index (A) was calculated by deriving the proportion of shared perturbed processes between all possible sample pairs as:
where P i and P j are the perturbed processes in samples i and j, respectively.
Complete linkage hierarchical clustering using Euclidean distance was performed on the resulting matrix. Clusters were visualised using ComplexHeatmap R package 75 .
Analysis of RNA sequencing data
Purified total RNA was extracted from 99 EACs from the ICGC cohort and sequenced as described previously 11 . RNA sequencing reads were then aligned to human reference genome hg19 and expression values were calculated using 
Gene editing
To induce ABI2 and NCOR2 gene knock-out (KO), the vector-free CRISPR-mediated editing approach was used as previously described 40 . Briefly, cells were cotransfected using lipofectamine CRISPR max (Life technologies) with a 69-mer tracrRNA (Sigma-Aldrich), three gene-specific crRNAs (Sigma-Aldrich, Supplementary Table 7 ) and GeneArt Platinum Cas9 nuclease (Life technologies).
To avoid off-target editing, all crRNAs used were verified to map only the gene of interest with a perfect match and additional hits in the genome with at least three mismatches. Control cells were transfected with the same protocol but using three non-targeting crRNAs. Gene editing was confirmed with Illumina Miseq sequencing.
The regions surrounding the targeted sites were amplified from genomic DNA of edited cells with primers containing Illumina adapters (Supplementary Table 7 Table 7 ) were called using the CrispRVariants package in R 78 and the percentage of edited alleles was estimated as the percentage of variant reads in each experiment.
Cell proliferation
Cell proliferation was measured every 24 hours for three days, starting three hours Conditions were compared using the one-tailed Student's t-test.
Flow cytometry
EdU incorporation and MCM loading were assessed using a modified version of the 
